
|Videos|October 20, 2016
High Cost Drug Launches and Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses lessons the specialty industry learned from the impact of high cost drug launches for hepatitis C and high cholesterol.
Advertisement
Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses lessons the specialty industry learned from the impact of high cost drug launches for hepatitis C and high cholesterol.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Predictive Models Could Address Missing Data in Advanced Prostate Cancer
2
Ivonescimab Significantly Extends OS Over Pembrolizumab in PD-L1-Positive Advanced NSCLC
3
FDA Approves Apitegromab-mstn, First Muscle-Targeted SMA Therapy
4
Beyond Cost Avoidance: Advancing Unit-Level Pharmaceutical Economics in Health Systems
5




































































































